Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 1/2018

01-07-2018 | Review Article

Role of toll-like receptor 4 (TLR4)-mediated interleukin-6 (IL-6) production in chemotherapy-induced mucositis

Authors: S. Khan, Hannah R. Wardill, J. M. Bowen

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2018

Login to get access

Abstract

Despite significant advances in our ability to treat cancer, cytotoxic chemotherapy continues to be the mainstay treatment for many solid tumours. Chemotherapy is commonly associated with a raft of largely manageable adverse events; however, gastrointestinal (GI) toxicity (also termed mucositis) remains a significant challenge with little in the way of preventative and therapeutic options. The inability to manage GI complications likely reflects our incomplete understanding of its aetiology and the idiosyncrasies of each chemotherapeutic agent. This review highlights aims to provide a narrative for the involvement of Toll-like receptor (TLR4) in the development of chemotherapy-induced GI mucositis, an already emerging theme within this field. Particular focus will be placed upon the signalling interaction between TLR4 and interleukin (IL)-6. This parallels recent preclinical findings showing that TLR4 knockout mice, which are protected from developing severe GI mucositis, completely lack an IL-6 response. As such, we suggest that this signalling pathway presents as a novel mechanism with potential for therapeutic intervention.
Literature
1.
Gibson RJ, Bowen JM, Coller JK (2015) What are the predictive factors in the risk and severity of chemotherapy-induced gastrointestinal toxicity? Future Oncol 11(17):2367–2370CrossRefPubMed
2.
Elting LS et al (2003) The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98(7):1531–1539CrossRefPubMed
3.
Keefe DM et al (1997) Effect of high-dose chemotherapy on intestinal permeability in humans. Clin Sci (Lond) 92(4):385–389CrossRef
4.
Wardill HR et al. (2014) TLR4/PKC-mediated tight junction modulation: a clinical marker of chemotherapy-induced gut toxicity? Int J Cancer 135(11):2483–2492CrossRefPubMed
5.
Cario E (2016) Toll-like receptors in the pathogenesis of chemotherapy-induced gastrointestinal toxicity. Curr Opin Support Palliat Care 10(2):157–164CrossRefPubMed
6.
Kelly D et al (2004) Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA. Nat Immunol 5(1):104–112CrossRefPubMed
7.
Eyking A et al (2011) Toll-like receptor 4 variant D299G induces features of neoplastic progression in Caco-2 intestinal cells and is associated with advanced human colon cancer. Gastroenterology 141(6):2154–2165CrossRefPubMedPubMedCentral
8.
Spiller S et al (2008) TLR4-induced IFN-gamma production increases TLR2 sensitivity and drives Gram-negative sepsis in mice. J Exp Med 205(8):1747–1754CrossRefPubMedPubMedCentral
9.
Sonis ST (2007) Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol 5(9 Suppl 4):3–11PubMed
10.
Logan RM et al (2008) Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 62(1):33–41CrossRefPubMed
11.
Velikova T et al (2017) Alterations in cytokine gene expression profile in colon mucosa of Inflammatory Bowel Disease patients on different therapeutic regimens. Cytokine 92:12–19CrossRefPubMed
12.
Logan RM et al (2007) The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 33(5):448–460CrossRefPubMed
13.
Wardill HR et al (2016) Irinotecan-induced gastrointestinal dysfunction and pain are mediated by common TLR4-dependent mechanisms. Mol Cancer Ther 15(6):1376–1386CrossRefPubMed
14.
Peterson DE et al (2011) Management of oral and gastrointestinal mucositis: ESMO clinical practice guidelines. Ann Oncol 22(Suppl 6):vi78–vi84PubMedPubMedCentral
15.
16.
Vouk K et al (2016) Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries. J Med Econ 19(9):900–912CrossRefPubMed
17.
Carlotto A et al (2013) The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue. Pharmacoeconomics 31(9):753–766CrossRefPubMed
18.
19.
20.
21.
Logan RM et al (2007) Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 43(4):395–401CrossRefPubMed
22.
Wardill HR et al (2014) Irinotecan disrupts tight junction proteins within the gut: implications for chemotherapy-induced gut toxicity. Cancer Biol Ther 15(2):236–244CrossRefPubMed
23.
Wardill HR et al (2016) TLR4-dependent claudin-1 internalization and secretagogue-mediated chloride secretion regulate irinotecan-induced diarrhea. Mol Cancer Ther 15(11):2767–2779CrossRefPubMed
24.
Wardill HR et al (2016) Tight junction defects are seen in the buccal mucosa of patients receiving standard dose chemotherapy for cancer. Support Care Cancer 24(4):1779–1788CrossRefPubMed
25.
Blijlevens NM, Donnelly JP, de Pauw BE (2005) Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplant. Bone Marrow Transplant 35(7):707–711CrossRefPubMed
26.
27.
Pereira VB et al (2016) A new animal model of intestinal mucositis induced by the combination of irinotecan and 5-fluorouracil in mice. Cancer Chemother Pharmacol 77(2):323–332CrossRefPubMed
28.
Kaczmarek A et al (2012) Severity of doxorubicin-induced small intestinal mucositis is regulated by the TLR-2 and TLR-9 pathways. J Pathol 226(4):598–608CrossRefPubMed
29.
Guabiraba R et al (2014) IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice. Mucosal Immunol 7(5):1079–1093CrossRefPubMedPubMedCentral
30.
31.
Wisplinghoff H et al (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39(3):309–317CrossRefPubMed
32.
Thorpe DW, Stringer AM, Gibson RJ (2013) Chemotherapy-induced mucositis: the role of the gastrointestinal microbiome and toll-like receptors. Exp Biol Med (Maywood) 238(1):1–6CrossRef
33.
34.
Pedroso SH et al (2015) Evaluation of mucositis induced by irinotecan after microbial colonization in germ-free mice. Microbiology 161(10):1950–1960CrossRefPubMed
35.
Stringer AM et al (2009) Gastrointestinal microflora and mucins may play a critical role in the development of 5-fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood) 234(4):430–441CrossRef
36.
Stringer AM et al (2008) Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhea model in rats. Cancer Biol Ther 7(12):1919–1925CrossRefPubMed
37.
Stringer AM et al (2009) Irinotecan-induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile. Int J Exp Pathol 90(5):489–499CrossRefPubMedPubMedCentral
38.
Montassier E et al (2014) 16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation. Microb Ecol 67(3):690–699CrossRefPubMed
39.
Montassier E et al (2015) Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther 42(5):515–528CrossRefPubMed
40.
Brandi G et al (2006) Intestinal microflora and digestive toxicity of irinotecan in mice. Clin Cancer Res 12(4):1299–1307CrossRefPubMed
41.
Tang Y et al (2017) Administration of probiotic mixture DM#1 ameliorated 5-fluorouracil-induced intestinal mucositis and dysbiosis in rats. Nutrition 33:96–104CrossRefPubMed
42.
Osterlund P et al (2007) Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer 97(8):1028–1034CrossRefPubMedPubMedCentral
43.
Motoori M et al (2017) Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients. Clin Nutr 36(1):93–99CrossRefPubMed
44.
Bowen JM et al (2007) VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther 6(9):1449–1454CrossRefPubMed
45.
Redman MG, Ward EJ, Phillips RS (2014) The efficacy and safety of probiotics in people with cancer: a systematic review. Ann Oncol 25(10):1919–1929CrossRefPubMed
46.
Wang YH et al (2016) The efficacy and safety of probiotics for prevention of chemoradiotherapy-induced diarrhea in people with abdominal and pelvic cancer: a systematic review and meta-analysis. Eur J Clin Nutr 70(11):1246–1253CrossRefPubMed
47.
Wardill HR et al (2018) Prophylactic probiotics for cancer therapy-induced diarrhoea: a meta-analysis. Curr Opin Support Palliat Care 12(2):187–197PubMed
48.
Wardill H et al (2016) Toll-like receptor 4 (tlr4)-mediated tight junction disruption and dysregulated ion secretion are key drivers of irinotecan-induced diarrhoea. Support Care Cancer 24(1):S60
49.
Greenhill CJ et al (2011) IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. J Immunol 186(2):1199–1208CrossRefPubMed
50.
Fukata M et al (2005) Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol 288(5):G1055–G1065CrossRefPubMed
51.
52.
53.
Logan RM et al (2008) Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther 7(7):1139–1145CrossRefPubMed
54.
Coller JK et al (2017) Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report. Cancer Chemother Pharmacol 79(2):431–434CrossRefPubMed
55.
Riehl T et al (2000) Lipopolysaccharide is radioprotective in the mouse intestine through a prostaglandin-mediated mechanism. Gastroenterology 118(6):1106–1116CrossRefPubMed
56.
Naugler WE, Karin M (2008) The wolf in sheep’s clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 14(3):109–119CrossRefPubMed
57.
Karin M, Lawrence T, Nizet V (2006) Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124(4):823–835CrossRefPubMed
58.
Morales-Rojas T et al (2012) Proinflammatory cytokines during the initial phase of oral mucositis in patients with acute lymphoblastic leukaemia. Int J Paediatr Dent 22(3):191–196CrossRefPubMed
59.
60.
Hayashi F et al (2001) The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410(6832):1099–1103CrossRefPubMed
61.
Shoenfelt J et al (2009) Involvement of TLR2 and TLR4 in inflammatory immune responses induced by fine and coarse ambient air particulate matter. J Leukoc Biol 86(2):303–312CrossRefPubMedPubMedCentral
62.
Demacker PN et al (2009) Plasma citrulline measurement using UPLC tandem mass-spectrometry to determine small intestinal enterocyte pathology. J Chromatogr B Anal Technol Biomed Life Sci 877(4):387–392CrossRef
Metadata
Title
Role of toll-like receptor 4 (TLR4)-mediated interleukin-6 (IL-6) production in chemotherapy-induced mucositis
Authors
S. Khan
Hannah R. Wardill
J. M. Bowen
Publication date
01-07-2018
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 1/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-018-3605-9

Other articles of this Issue 1/2018

Cancer Chemotherapy and Pharmacology 1/2018 Go to the issue

Original Article

Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer

Clinical Trial Report

Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males

Original Article

LAPTM4B gene copy number gain is associated with inferior response to anthracycline-based chemotherapy in hormone receptor negative breast carcinomas

Review Article

Interactions of lean soft-tissue and chemotherapy toxicities in patients receiving anti-cancer treatments

Original Article

UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy

Original Article

Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits